The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases
Open accessAbstract
Previous findings have suggested that class IIa histone deacetylases (HDACs) (HDAC4, -5, -7, and -9) are inactive on acetylated substrates, thus differing from class I and IIb enzymes. Here, we present evidence supporting this view and demonstrate that class IIa HDACs are very inefficient enzymes on standard substrates. We identified HDAC inhibitors unable to bind recombinant human HDAC4 while showing inhibition in a typical HDAC4 enzymatic assay, suggesting that the observed activity rather reflects the involvement of endogenous copurified class I HDACs. Moreover, an HDAC4 catalytic domain purified from bacteria was 1,000-fold less active than class I HDACs on standard substrates. A catalytic Tyr is conserved in all HDACs except for vertebrate class IIa enzymes where it is replaced by His. Given the high structural conservation of HDAC active sites, we predicted the class IIa His-Nε2 to be too far away to functionally substitute the class I Tyr-OH in catalysis. Consistently, a Tyr-to-His mutation in class I HDACs severely reduced their activity. More importantly, a His-976-Tyr mutation in HDAC4 produced an enzyme with a catalytic efficiency 1,000-fold higher than WT, and this “gain of function phenotype” could be extended to HDAC5 and -7. We also identified trifluoroacetyl-lysine as a class IIa-specific substrate in vitro . Hence, vertebrate class IIa HDACs may have evolved to maintain low basal activities on acetyl-lysines and to efficiently process restricted sets of specific, still undiscovered natural substrates.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Vertebrate class IIa HDACs carry a conserved active-site Tyr-to-His substitution that makes them very inefficient on canonical acetyl-lysine substrates, with most deacetylase activity in class IIa complexes coming from associated class I HDACs. A single His-to-Tyr mutation restores high catalytic activity, and trifluoroacetyl-lysine is identified as a class IIa-specific substrate in vitro.
Key findings
- The catalytic Tyr conserved in other HDACs is replaced by His in vertebrate class IIa HDACs; mutating HDAC3 Y298 to H abolished activity on pepH4-AcK16, and HDAC1 Y303H reduced activity 5- to 8-fold.
- HDAC4 catalytic domain purified from E. coli had measurable activity but was at least 1,000-fold lower than class I HDACs and 100-fold lower than the HDAC4-FLAG complex; it was inactive on pepH4-AcK16.
- HDAC4 H976Y produced a gain-of-function phenotype: >20-fold increased activity for HDAC4-FLAG and >1,000-fold for HDAC4-CD, reaching levels comparable to class I enzymes; similar effects were seen for HDAC5 H1006Y and HDAC7 H843Y.
- Trifluoroacetyl-lysine was identified as a class IIa-specific substrate in vitro, processed by HDAC4 full-length and catalytic domain and by three class IIa enzymes, but poorly by class I and class IIb HDACs.
Methods
- HDAC4 was used as a representative class IIa model with four approaches: HDAC inhibitor binding/inhibition comparison, functional analysis of purified HDAC4 catalytic domain expressed in E. coli, structure-guided mutagenesis, and substrate screening.
- Deacetylase assays used 3[H]acetyl-core histones purified from HeLa cells or fluorescent pepH4-AcK16, plus a commercial Fluor de Lys assay; HDAC inhibitor activities were measured by preincubation with enzymes before substrate addition.
- Binding was assessed by pull-down with biotinylated LAQ824/apicidin derivatives and by UV cross-linking; sequence analysis used CLUSTALW/Genedoc and structural analysis used bacterial class II homolog PDB 1ZZ1.
Limitations
- Stated: the lack of isotype/class-specific HDAC inhibitors limits distinguishing class IIa intrinsic activity from associated class I HDACs; attempts to obtain active recombinant class IIa HDACs in heterologous systems were unsuccessful, and it remains unknown whether this reflects missing cofactors or endogenous class I enzymes.
- Stated: the precise role of HDAC4 catalytic activity in atypical biological contexts remains to be elucidated, and identification of additional biological activities/substrates dependent on class IIa H-associated activity requires further work.
- Evident from the text: the study relies heavily on in vitro assays and ectopically expressed proteins, and no natural physiological class IIa-specific substrate is identified; the proposed specialized vertebrate class IIa activity is therefore inferred from synthetic substrate data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, we have identified trif luoroacetyl-lysine as a class IIa-specific substrate in vitro.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the Y298H substitution in HDAC3 did not affect its association with N-CoR DAD (Fig. 2B), suggesting that the integrity of the catalytic domain was preserved.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, replacement of Y with H produced a loss-of-function phenotype as severe as that caused by replacement with F (SI Fig. 8A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As predicted, replacing the active site Y with H was sufficient to abolish the enzymatic activity on a histone H4-derived peptide containing a single acetyl-lysine (pepH4-AcK16) (Fig. 2A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in SI Fig. 8C, the mutation actually reduced HDAC1 deacetylase activity 5-to 8-fold.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC Substrates.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Class IIa HDACs possess a weak but measurable intrinsic capability of hydrolyzing acetyl-lysines in vitro.”
- Also stated in: § HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs. · plain
“HDAC4-CD showed a measurable deacetylase activity both in the histone-based (Fig. 4B) and the commercial (SI Fig. 10A) HDAC assays.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Indeed, catalytic activity toward canonical HDAC substrates could be restored by a single H-to-Y substitution in the active site.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in SI Fig. 8E, mutation into F did not alter the activity of the purified HDAC4 complex on pepH4-AcK16.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Class IIa HDACs with the H Mutated into F Are Not Impaired in Their
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The H976Y mutation did not enhance HDAC4 transcriptional inhibitory activity, despite its clear effect on the enzymatic activity in vitro (SI Fig. 12 A).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When challenged in activity assays, HDAC4-CD showed a measurable deacetylase activity both in the histone-based (Fig. 4B) and the commercial (SI Fig. 10A) HDAC assays.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 23
- The quote only partly states this claim. 1
- Probably not a substantial claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the vertebrate class IIa HDACs, the catalytic Y is replaced by an H, a conservative substitution, whereas other functional residues are virtually always conserved (SI Fig. 7).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Sequence and Structure Analysis Indicates that Vertebrate Class IIa
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This protein was efficiently pulled-down on biotinylated LAQ824 beads (Fig. 4A), suggesting that the structural integrity of the catalytic domain was preserved in the recombinant truncated mutant.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, LAQ824 and apicidin had similar effects in this assay in contrast to the different inhibitory potencies and binding affinities shown in vitro.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Again Y mutants exhibited strongly increased activity compared with WT and, like the HDAC4 mutant, could be inhibited by LAQ824 but were resistant to apicidin.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pull-down was significantly reduced by preincubation with an excess of free LAQ824, whereas apicidin and MS275 did not show competition, thus confirming and directly validating the results obtained with ectopic HDAC4-FLAG.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Different than WT HDAC4-FLAG, Y mutants were sensitive only to the inhibitory effect of LAQ824, but they were highly resistant to inhibition by compounds belonging to different chemical classes (MS-275, apicidin, and its open derivative), all of which are active on class I HDACs (data not shown).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, HDAC4-CD was completely inactive on pepH4-AcK16 and on a number of acetylated peptides grafted from nonhistonic HDAC substrates (data not shown).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Having ascertained that class IIa HDACs are not proficient enzymes on acetyl-lysines, we sought alternative in vitro substrates.”
- Also stated in: § HDAC4 Compound Binding Assays. · boosted
“Here, we present evidence supporting this view and demonstrate that class IIa HDACs are very inefficient enzymes on standard substrates.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Identification of a Class IIa-Specific Substrate.
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § HDAC4 Compound Binding Assays. · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, this compound was actively and specifically processed by three different class IIa enzymes, whereas it was a poor substrate for both class I and class IIb HDACs (Fig. 6).”
- Also stated in: § Discussion · plain
“We have identified a class IIa-specific synthetic substrate, trifluoroacetyl-lysine.”
- Also stated in: § HDAC4 Compound Binding Assays. · plain
“Trifluoroacetyl-lysine is a class IIa-specific substrate in vitro.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Identification of a Class IIa-Specific Substrate.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified HDAC inhibitors unable to bind recombinant human HDAC4 while showing inhibition in a typical HDAC4 enzymatic assay, suggesting that the observed activity rather reflects the involvement of endogenous copurified class I HDACs.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Compound Binding Assays.
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, ascidian class IIa sequences also lack one of the conserved Zn ligands, a D is replaced by an S (SI Fig. 7).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In class IIa HDACs, three different residues (Y, H, and F) are observed at this position and, given the particular structural context, it is unlikely that for each residue a concomitant conformational change would occur.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Sequence and Structure Analysis Indicates that Vertebrate Class IIa
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This experimental evidence also proved the HDAC4 catalytic domain to be properly folded under our experimental conditions, because a single amino acid substitution was sufficient to confer high enzymatic activity.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the HDAC4-CD mutant showed an inhibition profile identical to that of the full-length HDAC4-FLAG mutant, suggesting that the observed selectivity is directly related to the catalytic domain and does not depend on additional N-terminal regions.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these results demonstrate that HDAC4 intrinsic catalytic activity is low on canonical acetylated substrates and does not contribute significantly to the overall activity observed in purified ectopic HDAC4 complexes.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4 Exhibits Weak Enzymatic Activity on Canonical HDAC Substrates in the Absence of Associated Endogenous Class I HDACs.
Load-bearingStrength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“All class IIa members expressed in mammalian cells are known to recruit class I HDACs, which possess high deacetylase activities both in vitro and in cells (18)(19)(20).”
What the sources say
- Not checked yetcites (18)(19)(20)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Remarkably, compounds that did not inhibit the H976Ysubstituted enzymes were those that did not bind WT HDAC4, thus implying that the mutant proteins retain the WT selectivity of interactions.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > An HDAC4 H976Y Mutation Restores Canonical Deacetylase Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It is well documented that class IIa HDACs are potent and selective transcriptional repressors (4).”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > HDAC4-Mediated Transcriptional Repression Does Not Depend on Its
What the sources say
- Not checked yetcites [4] source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This finding was confirmed both in the isolated catalytic domain expressed in a prokaryotic system as well as for the full-length enzymes expressed in mammalian cells, including HDAC5 and -7.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The emergent theme predicts class IIa HDACs with intrinsically different catalytic activities for the two groups: (i) canonical HDAC activity in invertebrates and (ii) a more specialized enzymatic activity in vertebrates.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- The authors state this as an assumption: The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mechanistically, the presence of the trifluoro group should destabilize the amide bond and thus favor the reaction even in the absence of transition-state stabilization, as postulated for the His-containing class IIa HDACs.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- The authors state this as an assumption: The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Mean values of at least two independent assays are reported.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Methods Sequence Analysis and Modeling.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our MEF2 reporter gene data are in agreement with these findings, excluding HDAC4 catalytic activity for being responsible for transcriptional repression and pointing to the involvement of class I enzymes that are equally sensitive to the inhibition by both LAQ824 and apicidin.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, our data also imply that class IIa HDACs should be considered a distinct class of therapeutic targets, concerning both their natural substrates and selective mechanisms of inhibition.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: Vertebrate class IIa HDACs have natural substrates that are not canonical acetyl-lysines.
- Rests on an assumption: In vitro substrate specificity of class IIa HDACs reflects their in vivo biological function.
None of the sources cited for this claim have been checked yet.
In the paper
“More recently, it has been shown that both Sirt1 (28) and HDAC3 (29), and not HDAC4 or -5, efficiently deacetylate MEF2D, thus contributing to MEF2Ddependent transcriptional repression.”
§ Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The authors state this as an assumption.
The catalytic mechanism of HDACs is conserved across the enzymes and species considered.
“Based on our results, the presence of an F should be incompatible with activity, provided that the catalytic mechanism is conserved.”
The paper relies on this without support.
Vertebrate class IIa HDACs have natural substrates that are not canonical acetyl-lysines.
“Future work will undoubtedly identify these yet unknown physiological substrates and further reveal the already complex biological activities of these enzymes.”
The paper relies on this without support.
In vitro substrate specificity of class IIa HDACs reflects their in vivo biological function.
“our results point to a previously unknown, specific catalytic activity of vertebrate class IIa HDACs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Class IIa enzymes (Lahm et al., 2007) as well as HDAC3 (Madsen and Olsen, 2012a), HDAC8 (Bradner et al., 2010), and HDAC11 (Inks et al., 2012) removed the physiologically non-relevant trifluoroacetamide (Ktfa).”
From Histone deacetylase 11 is an ε-N-Myristoyllysine hydrolase (2018) · cites this paper as Lahm et al., 2007
In the citing paper
“In vertebrates, this subfamily is characterized by limited catalytic activity, mainly due to the replacement of a tyrosine (Y) with a histidine (H) residue in the enzymatic pocket (Lahm et al., 2007).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Lahm et al., 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Claim of universal Tyr conservation overlooks ascidian class IIa homologs
MinorThe first statement says Tyr is conserved in every HDAC outside vertebrate class IIa enzymes. The paper later identifies ascidian class IIa homologs with Phe at that position; ascidians are not vertebrates.
“A catalytic Tyr is conserved in all HDACs except for vertebrate class IIa enzymes where it is replaced by His.”
“Yet another residue, F, is instead found in class IIa homologs of the ascidians Ciona intestinalis, Ciona savignyi, and Halocynthia roretzi.”
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Dent, S., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,906
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,856
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,497
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis
Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 805
Fischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 609
Toro, T. B., Bryant, J. R., & Watt, T. J. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00270 · Cited by 11
The impact of selective HDAC inhibitors on the transcriptome of early mouse embryos
Shao, R., Suzuki, T., Suyama, M., & Tsukada, Y.-I. (2024) · BMC Genomics · doi:10.1186/s12864-024-10029-3 · Cited by 11
Fiorentino, F., Fabbrizi, E., Raucci, A., Noce, B., Fioravanti, R., Valente, S., Paolini, C., Maria, R. D., Steinkühler, C., Gallinari, P., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202300655 · Cited by 11
Self-citationYoon, J. G., Lim, S.-K., Seo, H., Lee, S., Cho, J., Kim, S. Y., Koh, H. Y., Poduri, A., Ramakumaran, V. S., Vasudevan, P. C., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.06.015 · Cited by 11
HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond
Minisini, M., Mascaro, M., & Brancolini, C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.103 · Cited by 11
Characterization of the class IIa histone deacetylases substrate specificity
Kutil, Z., Meleshin, M., Baranova, P., Havlinova, B., Schutkowski, M., & Bařinka, C. (2022) · The FASEB Journal · doi:10.1096/fj.202101663r · Cited by 11
Histone Deacetylase Activity Assay
Peng, L., Yuan, Z., & Seto, E. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2474-5_7 · Cited by 11
Soriano, F. X., Chawla, S., Skehel, P., & Hardingham, G. E. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12058 · Cited by 11
Александрович, Ю. П., Aleksandrova, Y. R., & Неганова, М. Е. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178629 · Cited by 14
Chinellato, M., Perin, S., Carli, A., Lastella, L., Biondi, B., Borsato, G., Giorgio, E. D., Brancolini, C., Cendron, L., & Angelini, A. (2024) · Journal of Molecular Biology · doi:10.1016/j.jmb.2024.168541 · Cited by 10
Foxp3 inhibits HDAC1 activity to modulate gene expression in human T cells
Holmes, D., Gao, J., & Su, L. (2011) · Virology · doi:10.1016/j.virol.2011.09.002 · Cited by 10
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137)
Simões‐Pires, C. A., Bertrand, P., & Cuendet, M. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1282945 · Cited by 10
HDACs in Skeletal Muscle Remodeling and Neuromuscular Disease
Simmons, B. J., Cohen, T. J., Bedlack, R., & Yao, T. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_5 · Cited by 9
Schweipert, M., Nehls, T., Wurster, E., Böltner, J., Anton, K., Lammer, P., Lermyte, F., & Meyer‐Almes, F. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107883 · Cited by 8
Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses
Christensen, L. M., & Hancock, W. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909816 · Cited by 11
Kim, G. S., Jung, H.-E., Kim, J., & Lee, Y. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132680 · Cited by 8
Developing novel non-hydroxamate histone deacetylaseinhibitors: the chelidamic warhead
Valente, S., Conte, M., Tardugno, M., Nebbioso, A., Tinari, G., Altucci, L., & Mai, A. (2011) · MedChemComm · doi:10.1039/c1md00249j · Cited by 8
Signals for antigen-independent differentiation of memory CD8+ T cells
Kwesi‐Maliepaard, E. M., Jacobs, H., & van Leeuwen, F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03912-9 · Cited by 8
Grewal, C., Hickmott, J. W., Rentas, S., & Karagiannis, J. (2012) · Cell Division · doi:10.1186/1747-1028-7-13 · Cited by 9
Distribution and diversity of classical deacylases in bacteria
Graf, L. G., Moreno–Yruela, C., Qin, C., Schulze, S., Palm, G. J., Schmöker, O., Wang, N., Hocking, D. M., Jebeli, L., Girbardt, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53903-0 · Cited by 7
Modulating the Secretome of Fat to Treat Heart Failure
Salyer, L. G., Wang, Y., Ma, X., Foryst‐Ludwig, A., Kintscher, U., Chennappan, S., Kontaridis, M. I., & McKinsey, T. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325593 · Cited by 8
Xu, L., Xie, H., Hu, S., Zhao, X., Han, M., Liu, Q., Feng, P., Wang, W., & Li, C. (2022) · Acta Physiologica · doi:10.1111/apha.13802 · Cited by 7
Malinow, R. A., Zhu, M., Jin, Y., & Kim, K. W. (2022) · Scientific Reports · doi:10.1038/s41598-022-20361-x · Cited by 7
Trifluoroacetyl Lysine as a Bromodomain Binding Mimic of Lysine Acetylation
Miller, G. M., Flynn, E. M., Tom, J., Song, A., & Cochran, A. G. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00016 · Cited by 7
Exploring Therapeutic Potential of 1,3,4-Oxadiazole Nucleus as Anticancer Agents: A Mini-review
Bukhari, A., Nadeem, H., Sarwar, S., Abbasi, I., Khan, M. T., Hamid, I., & Bukhari, U. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220608120908 · Cited by 7
HDAC Inhibitors as Novel Therapeutics in Aging and Alzheimer’s Disease
Nott, A., Fass, D. M., Haggarty, S. J., & Tsai, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391494-1.00008-2 · Cited by 8
Enzyme-independent functions of HDAC3 in the adult heart
Qian, S., Zhang, C., Li, W., Song, S., Lin, G., Cheng, Z., Zhou, W., Yin, H., Wang, Y., Li, H., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.002 · Cited by 6
Yue, R.-Z., Guo, X., Li, C.-J., Wu, L.-J., Liu, Y., Hu, J., Yan, B.-K., Lin, H.-T., Tang, Y., Yan, W., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03603-3 · Cited by 6
Scaffolding Activities of Pseudodeacetylase HDAC7
Kodikara, I. K. M., & Pflum, M. K. H. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00753 · Cited by 6
Wood, D. J., Tsvetkov, E., Comte‐Walters, S., Welsh, C. L., Bloyd, M., Wood, T. G., Akiki, R. M., Anderson, E. M., Penrod, R. D., Madan, L. K., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.01.027 · Cited by 6
Determination of Protein Lysine Deacetylation
Ellis, D. J. P., Yuan, Z., & Seto, E. (2008) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps1412s54 · Cited by 6
Medicinal chemistry of histone deacetylase inhibitors
Ružić, D., Djoković, N., Nikolic, K. M., & Vujić, Z. B. (2021) · Arhiv za farmaciju · doi:10.5937/arhfarm71-30618 · Cited by 6
Cadet, J. L. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150121230133 · Cited by 6
Liu, H., Zhang, F., Wang, K., Tang, X., & Wu, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp02261a · Cited by 6
Histone Deacetylase Inhibitors
JONES, P. G. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627073.ch9 · Cited by 6
Self-citationGuo, Y., Li, J., Liu, X., Ding, H., & Zhang, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1571276 · Cited by 5
Bozdağ, M., Mroweh, N., Raucci, A., Angeli, A., Peppicelli, S., Biagioni, A., Calorini, L., Trisciuoglio, D., Ragno, R., Astolfi, R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01788 · Cited by 5
A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis
Poon, E. K. Y., Liu, L., Wu, K., Lim, J., Sweet, M. J., Lohman, R., Iyer, A., & Fairlie, D. P. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17306 · Cited by 5
Hassan, O., Pizzagalli, M. D., Leary, O. P., Zepecki, J. P., Corseri, A., Wu, L. J., Sasipalli, S., Lee, D., Hayward, L., Tran, L. H., et al. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110732 · Cited by 5
Expanded CAG/CTG repeats resist gene silencing mediated by targeted epigenome editing
Yang, B., Borgeaud, A. C., Buřičová, M., Aeschbach, L., Rodríguez‐Lima, O., Buendía, G. A. R., Cinesi, C., Taylor, A. S., Baubec, T., & Dion, V. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab255 · Cited by 5
Mattu, M., Giovine, P. D., Steinkühler, C., Francesco, R. D., Altamura, S., Cecchetti, O., Carfı́, A., & Barbato, G. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.03.028 · Cited by 5
Self-citationKozlov, M. V., Malikova, A. Z., Kamarova, K. A., Konduktorov, K. A., & Kochetkov, S. N. (2018) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162018040118 · Cited by 5
Epigenetic Approaches to the Treatment of Renal Cell Cancer
Hong, S. H., Lee, J., Jang, E. B., Park, S. Y., Moon, H. S., & Yoon, Y. E. (2020) · Journal of Urologic Oncology · doi:10.22465/kjuo.2020.18.2.78 · Cited by 5
Lei, Y., Chen, Y., Guo, M., Patel, F., Bai, Y., Goo, B. M. S. S., Du, Q., Weintraub, N. L., & Lu, X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03556-w · Cited by 5
Tan, W. J., Hawley, H. R., Wilson, S. J., & Fitzsimons, H. L. (2024) · BMC Biology · doi:10.1186/s12915-023-01800-1 · Cited by 4
Wang, Y., Curson, J. E. B., Ramnath, D., Gupta, K. D., Reid, R. C., Karunakaran, D., Fairlie, D. P., & Sweet, M. J. (2024) · Biochemical Journal · doi:10.1042/bcj20240380 · Cited by 4
Depression: epigenetics and epitranscriptomic modifications
Banerjee, S., Shrilaxmi, M. S., Banerjee, S., Prajwal, B. G., Smith, C., D’Mello, S. R., & Dastidar, S. G. (2025) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2025.2602171 · Cited by 4
Molecular Structure and Function of Zinc-Dependent Histone Deacetylases
Christianson, D. W. (2026) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-051424-053005 · Cited by 4
Histone Deacetylases as Cancer Chemoprevention Targets for Natural Products
Ho, R., Nievergelt, A., Pires, C. S., & Cuendet, M. (2012) · Studies in natural products chemistry · doi:10.1016/b978-0-444-59530-0.00009-5 · Cited by 4
Guise, A. J., & Cristea, I. M. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_5 · Cited by 4
Purification of metal-dependent lysine deacetylases with consistently high activity
Toro, T. B., Painter, R. G., Haynes, R. A., Glotser, E. Y., Bratton, M. R., Bryant, J. R., Nichols, K. A., Matthew-Onabanjo, A. N., Matthew, A. N., Bratcher, D. R., et al. (2017) · Protein Expression and Purification · doi:10.1016/j.pep.2017.08.009 · Cited by 4
Catalytic-independent neuroprotection by SIRT1 is mediated through interaction with HDAC1
Pfister, J. A., Ma, C., & D’Mello, S. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215208 · Cited by 4
Present and future perspectives for targeting histone modifications in therapy
Camilo, V., & Jerónimo, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00018-0 · Cited by 4
Emerging roles of histone deacetylases in adaptive thermogenesis
Zhou, R., Cao, Y., Xiang, Y., Fang, P., & Shang, W. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124408 · Cited by 4
Kollár, J., & Frecer, V. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.08.008 · Cited by 4
Protein Acetylation as an Integral Part of Metabolism in Cancer Development and Progression
Čuperlović‐Culf, M., & Culf, A. S. (2014) · Cited by 4
Epigenetic Treatment Options in Urothelial Carcinoma
Pinkerneil, M., Hoffmann, M. J., & Niegisch, G. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7234-0_21 · Cited by 4
Structural Biology of Epigenetic Targets
Romier, C., Wurtz, J., Renaud, J., & Cavarelli, J. (2009) · Methods and principles in medicinal chemistry · doi:10.1002/9783527627073.ch2 · Cited by 4
Histone Deacetylases, the Erasers of the Code
Lamberti, M. J., Vera, R. E., Vittar, N. B. R., & Schneider, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802389-1.00009-5 · Cited by 3
HDAC7 influences ER-⍺ transcription via NCoR-HDAC3 dissociation
Kodikara, I. K. M., Nwanelo, V. O., Belanger, A. K., & Pflum, M. K. H. (2025) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2025.141083 · Cited by 3
Histone deacetylase 7 mediates lipopolysaccharide-inducible mitochondrial fission in macrophages
Abrol, R., Afroz, S. F., Curson, J. E. B., Raven, K. D., Gupta, K. D., Gunther, K. S., Jones, A., Reid, R. C., Xiong, Z., Gunter, J. H., et al. (2025) · Journal of Cell Science · doi:10.1242/jcs.264376 · Cited by 3
Closer to class IIa HDAC inhibitors
Baas, T. (2013) · Science-Business eXchange · doi:10.1038/scibx.2013.301 · Cited by 3
Hydroxamic Acids as Histone Deacetylase Inhibitors
Thaler, F., Patil, V. M., & Gupta, S. P. (2013) · Springer eBooks · doi:10.1007/978-3-642-38111-9_5 · Cited by 3
A GSH-resistant FK228 analogue containing a stable disulfide bond
Zhan, M., Xing, Y., Li, Z., & Yin, F. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107119 · Cited by 3
Dang, Z., Li, H., Xue, S., Shao, B., Ning, Y., Su, G., Zhang, F., Yu, W., & Leng, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116396 · Cited by 3
Zhang, L., Xie, F., Zhang, F., & Lu, B. (2024) · Medicine · doi:10.1097/md.0000000000037994 · Cited by 3
Ganai, S. A. (2020) · Springer eBooks · doi:10.1007/978-981-15-8179-3_3 · Cited by 3
Elmezayen, A. D., Al-Obaidi, A., & Yelekçi, K. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107937 · Cited by 3
Inhibitors of the Zinc‐Dependent Histone Deacetylases
Kristensen, H. M. E., Madsen, A. S., & Olsen, C. A. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527809257.ch7 · Cited by 3
Resolving the Deceptive Isoform and Complex Selectivity of HDAC1/2 InhibitorsPreprint
Mazitschek, R., & Payne, N. C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3960267 · Cited by 3
Lyu, H., Ishimura, A., Suzuki, R., Buyanbat, K., Batbayar, G., Meguro‐Horike, M., Horike, S., Yano, S., & Suzuki, T. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102016 · Cited by 2
Sears, T. K., McCord, M., Wang, W., Steffens, A., McCortney, K., Chaliparambil, R. K., Sarkaria, J. N., & Horbinski, C. (2025) · JCI Insight · doi:10.1172/jci.insight.195385 · Cited by 2
Hawley, H. R., Sutherland‐Smith, A. J., Savoian, M. S., & Fitzsimons, H. L. (2025) · Open Biology · doi:10.1098/rsob.250095 · Cited by 2
Barone, S., Bello, I., Filocamo, G., Cerchia, C., Guadagni, A., Brunetti, M., Cosentino, E. G., Hanl, M., König, B., Esposito, C., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118806 · Cited by 2
Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors
Rai, C., Ruan, H., Li, X., Li, W., Jeong, H.-H., Song, C., Liu, P., Chang, Y., Fang, H., Udhaya Kumar., S., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02698-1 · Cited by 2
Bree, B. A. V., & Eichner, L. J. (2026) · Science Advances · doi:10.1126/sciadv.aee7295 · Cited by 2
Liu, Y., Liu, X., Dong, X., Yin, Z., Xie, Z., & Luo, Y. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03539-22 · Cited by 2
Design and synthesis of peptides as stabilizers of histone deacetylase 4
Lill, A., Schweipert, M., Nehls, T., Wurster, E., Lermyte, F., Meyer‐Almes, F., & Schmitz, K. (2024) · Journal of Peptide Science · doi:10.1002/psc.3603 · Cited by 2
Phenotypic Manifestations of a New Variant in HDAC4 Gene
Ianniello, M., Angelis, V. D., Ottaiano, A., Ruggiero, R., Sirica, R., Petrillo, N., Fico, A., Cerbone, T., Rosania, C., Mormile, R., et al. (2025) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.33029 · Cited by 2
Age-Related Changes in Neuroinflammation and Epigenetic Regulation in Mouse Ischemic Stroke Model
Kondo, M., Tamura, H., Segi‐Nishida, E., & Hasegawa, H. (2025) · Brain Sciences · doi:10.3390/brainsci15080810 · Cited by 3
Singer, B. D., & D’Alessio, F. R. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.51 · Cited by 2
Bürli, R. W., Thomas, E. A., & Beaumont, V. (2010) · Topics in medicinal chemistry · doi:10.1007/7355_2010_10 · Cited by 2
Promotion of Anchorage-independent Growth by Cytoplasmic and Nuclear Histone Deacetylase 9
Yura, T., Hashizume, H., Suzuki, E., Imagawa, M., & Osada, S. (2010) · Eisei kagaku · doi:10.1248/jhs.56.581 · Cited by 2
Epigenetic and Signaling Pathway Regulation in Hair Cell Regeneration
Li, H. (2015) · Cellular & Molecular Medicine Open access · doi:10.21767/2573-5365.100006 · Cited by 2
Acetylation and Methylation in Asthma, COPD, and Lung Cancer
Zwinderman, M. R. H., Cao, F., & Dekker, F. J. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_81 · Cited by 2
The Role of Epigenetics in Cardiovascular Disease
Zhou, B., Margariti, A., & Xu, Q. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-388415-2.00020-2 · Cited by 2
Transcriptional Regulation of Memory Formation
Chatterjee, S., & Abel, T. G. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21107-3 · Cited by 4
Temporal and Spatial Regulation of Histone Deacetylase-7 and β-Catenin in Endothelial Cells
Hui, S., Brunt, K. R., & Husain, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.219345 · Cited by 2
Selective class IIa HDAC inhibition reverses diastolic dysfunction in cardiometabolic HFpEFPreprint
Huang, J., Schreiter, F. C., Fan, J., Chen, Z., Paluvai, H., Withaar, C., Oeing, C. U., Saadatmand, A. R., Schoger, E., Haydar, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.14.699428 · Cited by 2
Transcriptional and epigenetic regulation of memory storage
Abel, T. G., Basu, B., & Chatterjee, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15754-7.00076-6 · Cited by 1
Wang, X., Wang, L., Li, D., Liu, Y., Shang, Q., Liu, Y., Zhang, L., Xu, Z., Huang, C., & Song, C. (2025) · Veterinary Microbiology · doi:10.1016/j.vetmic.2025.110520 · Cited by 1
Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery
Wang, J.-J., Gao, Y., Ji, X.-Q., Yin, J.-Y., Zhang, M., Wang, B., Liu, H., Feng, S., Wang, N., Lu, G., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70052 · Cited by 2
Histone Deacetylase Functions in Epidermal Development, Homeostasis and Cancer
Brennan-Crispi, D. M., & Millar, S. E. (2018) · Contributions to management science · doi:10.1007/978-3-319-16769-5_5 · Cited by 1
Morse, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-814809-9.00002-0 · Cited by 1
Gene Regulation by Nuclear Calcium and Its Antagonism by NMDAR/TRPM4 Signaling
Pruunsild, P., Bengtson, C. P., Yan, J., Bading, H., & Hagenston, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-68550-7_4 · Cited by 1
Ononye, S. N. (2013) · OpenCommons at University of Connecticut (University of Connecticut) · Cited by 1
The Role of Histone Deacetylases in Cytokine Regulation in Human Gestational Tissues
Munro, S. K. (2013) · ResearchSpace (University of Auckland) · Cited by 1
Development Of Novel Radiotracers For Pet Imaging Of Hdac-Mediated Epigenetic Regulation
Bonomi, R. E. (2016) · Human Biology · Cited by 1
Kwapis, J. L., Alaghband, Y., Kramár, E. A., López, A. J., Ciernia, A. V., White, A. O., Shu, G., Rhee, D., Michael, C. M., Montellier, E., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/301135 · Cited by 1
Metadata
- Authors
- Lahm, A., Paolini, C., Pallaoro, M., Nardi, M. C., Jones, P., Neddermann, P., Sambucini, S., Bottomley, M. J., Lo Surdo, P., Carfı́, A., Koch, U., De Francesco, R., Steinkühler, C., & Gallinari, P.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Istituto di Ricerche di Biologia Molecolare, I.R.B.M., P. Angeletti, 00040 Pomezia, Italy
- Corresponding author
- Gallinari, P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-10-30
- Volume
- 104
- Issue
- 44
- Pages
- 17335-17340
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2077257
- OpenAlex
- W2152631096
- Cited by
- 566
- References
- 36
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 40 · 2023: 15 · 2022: 32 · 2021: 33 · 2020: 32 · 2019: 37 · 2018: 31 · 2017: 29 · 2016: 31 · 2015: 44 · 2014: 29 · 2013: 39 · 2012: 34
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- class IIa histone deacetylases, HDAC4, HDAC5, HDAC7, HDAC9, catalytic efficiency, histone deacetylase inhibitors, class I HDACs, catalytic tyrosine, enzyme evolution, substrate specificity
- MeSH terms
- Amino Acid Sequence, Animals, Binding Sites, Catalysis, Enzyme Activation, HeLa Cells, Histidine, Histone Deacetylases, Humans, Models, Molecular, Mutation, Substrate Specificity, Urochordata, Vertebrates, Protein Structure, Tertiary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
